Multimodality therapy in mesothelioma: Role of chemotherapy

Thoracic Surgery Clinics

Volumn 14, Issue 4 SPEC. ISS., 2004, Pages 531-542

  Vogelzang, Nicholas J ^a  

^a NEVADA CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FOLIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; NITROSOUREA; OXALIPLATIN; PACLITAXEL; PEMETREXED; PROCARBAZINE; RALTITREXED; TOPOTECAN; TRIMETREXATE; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER SURGERY; CAUSE OF DEATH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKOPENIA; META ANALYSIS; NAUSEA; NEUTROPENIA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 4744375249     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2004.06.010     Document Type: Review

References (55)

1. SEER US Department of Health and Human Services. Health. Special excerpt: trend tables on 65 and older population. Deaths from selected occupational diseases for persons 15 years of age and over: United States, selected years 1980â€"2000. Surveillance, Epidemiology, End Results Program of the National Cancer Institute Available at: http://www.seer.cancer.gov. Accessed June 2004
2. R.R. Connelly Sr, M.H. Myers, C.L. Percy, and J.F. Fraumeni Jr Demographic patterns for mesothelioma in the United States J Natl Cancer Inst 78 1987 1053 1060
3. J. Peto, A. Decarli, C. La Vecchia, F. Levi, and E. Negri The European mesothelioma epidemic Br J Cancer 79 1999 666 672
4. B. Price Analysis of current trends in United States mesothelioma incidence Am J Epidemiol 145 1997 211 218
5. N. Vogelzang, S. Emri, M. Boyer, U. Gatzemeier, D. Jablons, and R. Taub Effect of folic acid and vitamin B12 supplementation on risk-benefit ratio from phase III study of pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument [abstract 2644] Proc Am Soc Clin Oncol 22 2003 657
6. N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie A phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
7. J. Symanowski, J. Rusthoven, B. Nguyen, P. Ruffie, D. Moro-Sibilot, and G. Dabouis Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma [abstract 2602] Proc Am Soc Clin Oncol 22 2003 647
8. S. Ong, and N. Vogelzang Chemotherapy in malignant pleural mesothelioma: a review J Clin Oncol 14 1996 1007 1017
9. P. Janne Chemotherapy for malignant pleural mesothelioma Clin Lung Cancer 5 2003 98 106
10. H. Kindler Malignant pleural mesothelioma Curr Treat Options Oncol 14 2000 313 326
11. R. van Klaveren, J. Aerts, H. de Bruin, G. Biaconne, C. Manegold, and J. van Meerbeeck Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma Lung Cancer 43 2004 63 69
12. S. Armato, G. Oxnard, H. MacMahon, N. Vogelzang, H. Kindler, and A. Starkey Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques Med Phys 31 2004 1105 1115
13. G. Scagliotti, C. Kortsick, D. Castellano, G. Dark, A. Price, and R. Rosell Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer Abstract no. 2513 Proc Am Soc Clin Oncol 22 2003 625
14. J. Van Meerbeeck, C. Manegold, R. Gaafar, R. Van Klaveren, M. Vincent, and C. Legrand A randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the EORTC Lung Cancer Group and NCIC [abstract 7021] Proc Am Soc Clin Oncol 23 2004
15. T. Berghmans, M. Paesmans, Y. Lalami, I. Louviaux, S. Luce, and C. Mascaux Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis Lung Cancer 38 2002 111 121
16. C. Delbaldo, N. Syz, S. Michiels, T. Le Chevalier, and J-P. Pignon Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma (NSCLC): a meta-analysis of the literature [abstract 2507] Proc Am Soc Clin Oncol 22 2003 623
17. N. Hanna, F. Shepherd, F. Fossella, J. Pereira, F. De Marinis, and J. von Pawel Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
18. C. Shih, L. Habeck, L. Mendelsohn, V. Chen, and R. Schultz Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA) Adv Enzyme Regul 38 1998 135 152
19. E. Taylor, D. Kuhnt, C. Shih, S. Rinzel, G. Grindey, and J. Barredo A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase J Med Chem 35 1992 4450 4454
20. C. Shih, V. Chen, L. Gossett, S. Gates, W. MacKellar, and L. Habeck LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res 57 1997 1116 1123
21. Y. Wang, R. Zhao, S. Chattopadhyay, and I. Goldman A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed Cancer Res 62 2002 6434 6437
22. V. Chen, J. Bewley, S. Andis, R. Schultz, P. Iversen, and C. Shih Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells Br J Cancer 78 Suppl 3 1998 27 34
23. D. Rinaldi, H. Burris, F. Dorr, J. Woodworth, J. Kuhn, and J. Eckardt Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation J Clin Oncol 13 1995 2842 2850
24. E. Bajetta, L. Celio, R. Buzzoni, L. Ferrari, A. Marchiano, and A. Martinetti Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer Ann Oncol 14 2003 1543 1548
25. R. Zinner, C.K. Obasaju, F.Z. Fossella, V.A. Pappadimitrakopoulou, K.M.W. Pister, and M.R. O'Day Alimta plus carpoplatin (AC) in patients (pts) with advanced non small cell lung cancer (NSCLC): a phase II trial Abstract no. 2580 Proc Am Soc Clin Oncol 22 2003 652
26. M. Edelman Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials Clin Lung Cancer 4 Suppl 2 2003 S40 S44
27. R. Thodtmann, H. Depenbrock, H. Dumez, J. Blatter, R. Johnson, and A. van Oosterom Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin J Clin Oncol 17 1999 3009 3016
28. L. Mendelsohn, S. Gates, L. Habeck, K. Shackelford, J. Worzalla, and C. Shih The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol Adv Enzyme Regul 36 1996 365 381
29. C. Niyikiza, S. Baker, D. Seitz, J. Walling, K. Nelson, and J. Rusthoven Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy Mol Cancer Ther 1 2002 545 552
30. P. Paoletti, M. Pistolesi, J.J. Rusthoven, J.T. Symanowski, and J. Blatter Correlation of pulmonary function tests with best tumor response status: results from the phase III study of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma [abstract 2651] Proc Am Soc Clin Oncol 22 2003 659
31. R. Gralla, P. Hollen, and A.M. Liepa Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument Proc Am Soc Clin Oncol 39 2003 2496A
32. M. Byrne, J. Davidson, A. Musk, J. Dewar, G. van Haze, and M. Buck Cisplatin and gemcitabine treatment for malignant pleural mesothelioma: a phase II study J Clin Oncol 17 1999 25 30
33. V. Rusch Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol 21 2003 2629 2630
34. A. Hughes, P. Calvert, A. Azzabi, R. Plummer, R. Johnson, and J. Rusthoven Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma J Clin Oncol 20 2002 3533 3544
35. A. Nowak, M. Byrne, R. Williamson, G. Ryan, A. Segal, and D. Fielding A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma Br J Cancer 87 2002 491 496
36. B. Castagneto, S. Zai, and V. Dongiovanni Cisplatin and gemcitabine in malignant pleural mesthelioma: a phase II study Proc Am Soc Clin Oncol 22 2003 656
37. J. van Haarst, P. Baas, C. Manegold, J. Schouwink, J. Burgers, and H. de Bruin Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma Br J Cancer 86 2002 342 345
38. C. Pinto, A. Marino, and V. Manzini Sequential chemotherapy with cisplatin/gemcitabine followed by mitoxantrone/methotrexate/mitomycin in untreated malignant pleural mesothelioma: a multicenter Italian phase II study [abstract] Proc Am Soc Clin Oncol 22 2003 650A
39. C. Manegold, J. Symanowski, and U. Gatzemeier Secondary (post-study) chemotherapy in phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma is associated with longer survival Proc Am Soc Clin Oncol 39 2003 2684A
40. A.G. Favaretto, S.M. Aversa, A. Paccagnella, P. Manzini Vde, V. Palmisano, and F. Oniga Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study Cancer 97 2003 2791 2797
41. W. Schuette, T. Blankenburg, K. Layerwald, J. Schreiber, I. Bork, and B. Wollsckaeger A multicenter phase II study of gemcitabine and oxalplatin for malignant pleural mesothelioma Clin Lung Cancer 4 2003 294 297
42. N. Vogelzang A multicentre phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma [letter] Clin Lung Cancer 5 2003 63 64
43. P. Baas, A. Andizzoni, and F. Grossi The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992) Eur J Cancer 39 2003 353 357
44. K. Fizazi, H. Doubre, T. Le Chevalier, A. Riviere, J. Viala, and C. Daniel Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study J Clin Oncol 21 2003 349 354
45. S. Dubey, and J. Schiller Chemotherapy for advanced non-small cell lung cancer Hematol Oncol Clin North Am 18 2004 101 114
46. P.A. Janne, G. Obasaju, R. Simon, K. Taub, P. Kelly, and L.P. Fidias A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM) Journal of Clinical Oncology 22 2004 14S
47. G. Giaccone, R. Herbst, C. Manegold, G. Scagliotti, R. Rosell, and V. Miller Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trialâ€"INTACT 1 J Clin Oncol 22 2004 777 784
48. A. Chahinian Malignant mesothelioma: radiotherapy and chemotherapy B. Robinson A. Chahinian Mesothelioma 2002 Martin Dunitz London 209 273
49. A. Alberts, G. Falkson, L. Goedhals, D. Vorobiof, and C. Van der Merwe Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers J Clin Oncol 6 1988 527 535
50. S. Yajnik, K. Rosenzweig, B. Mychalczak, L. Krug, R.M. Flores, and L. Hong Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesthelioma Int J Radiat Oncol Biol Phys 56 2003 1319 1326
51. D.J. Sugarbaker, R.M. Flores, M.T. Jaklitsch, W.G. Richards, G.M. Strauss, and J.M. Corson Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients J Thorac Cardiovasc Surg 117 1999 54 63
52. P. Kestenholz, C. Taverna, M. Jörger, S. Bodis, W. Weder, and R. Stahel Neoadjuvant chemotherapy and extrapleural pneumonectomy (EPP) in malignant pleural mesothelioma (abstract no. 157) Eur J Cancer 37 Suppl 6 2001 46
53. W. Weder, T. Kastenholz, C. Taverna, S. Bodis, D. Lardinois, and M. German Neoadjuvant chemotherapy followed by extrapleural pneumonectomy I malignant mesothelioma J Clin Oncol 22 2004 3451 3457
54. R. Stahel, W. Weder, P. Ballabeni, D. Betticher, R. Schmid, and R. Stupp Neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma (MPM): a multicenter phase II trial of the SAKK [abstract 7052] J Clin Oncol 22 2004
55. R. Flores, L. Krug, K. Rosenzweig, A. Vincent, T. Akhurst, and R. Heelan Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM) [abstract 7193] J Clin Oncol 22 2004